Skin testing, computerized support tool can improve antibiotic use in hospital inpatients

March 6, 2017, Massachusetts General Hospital
The treatment guideline/decision support tool used to determine whether patients with penicillin allergy in their medical record could safely receive penicillin-related antibiotics was accessible via this secure smartphone app or hospital desktop computers. Credit: Brett Macaulay, Division of Infectious Diseases, Massachusetts General Hospital

Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) investigators have developed two approaches to increasing the use of penicillins and cephalosporins - highly effective antibiotics that are not as problematic as many alternatives - in hospitalized patients previously believed to be allergic to penicillin. Their report, which has been published online in the Journal of Allergy and Clinical Immunology, describes how both tested protocols—use of penicillin allergy skin tests or a computerized guideline/decision support tool—safely increased the use of penicillin and penicillin-related antibiotics in inpatients.

"From 10 to 15 percent of hospitalized patients have in their medical record, but studies have shown that more than 95 percent are not really allergic," explains Kimberly Blumenthal, MD, MSc, of the Division of Rheumatology, Allergy and Immunology, the Medical Practice Evaluation Center, and the Lawrence Center for Quality and Safety at MGH, co-lead and corresponding author of the JACI paper. "We know that over-reporting of penicillin allergies has a negative impact on patient care, as the alternative drugs often used are less effective, more toxic and can both leave patients vulnerable to dangerous C. difficile infection and increase antibiotic resistance in the community. The need to address over-reported penicillin allergy has been widely acknowledged, but how to do that has remained unclear."

"This study offered a unique opportunity to examine what strategy best serves inpatients who have this listed allergy," explains co-lead author Paige Wickner, MD, MPH, of the BWH Division of Rheumatology, Immunology and Allergy and the Department of Quality and Safety.

Over a two-year period—June 2014 to June 2016—the investigators compared three approaches to treating BWH inpatients who needed antibiotic treatment and had a recorded penicillin allergy. During the first five months, patients on the medical service received standard of care treatment, with testing via either skin test or test dosing conducted only after referral by the primary care team and consultation with an allergy specialist.

During the next seven months, inpatients with a recorded penicillin allergy who needed were screened for skin-test eligibility. Those with a history of more serious allergic reactions or those taking drugs that could interfere with skin testing were ineligible, and testing also required consent of the patient and the care team. Patients whose skin test was negative and safely tolerated an oral dose of amoxicillin - a form of penicillin in the same beta-lactam antibiotic class as cephalosporins - were determined not to be allergic.

During the third seven-month period, physicians had access to a computerized treatment guideline and decision support system, which - based on details of the reported allergic reaction, such as whether the patient experienced a rash, fever or joint pain - categorized the reaction as follows:

  • very low risk - full dose of penicillin or cephalosporin
  • low risk - reduced test dose of penicillin or cephalosporin
  • medium/high risk - consult with an allergy specialist
  • serious reaction - avoid penicillin or cephalosporin.

Due to logistical issues, including schedule coordination and the inability to conduct tests on more than one patient at a time, only 43 of the 179 patients (24 percent) who would have been eligible for skin testing actually had the test. But while that did not result in a significant increase between the standard-of-care and skin-test periods in the overall percentage of those receiving penicillin or cephalosporin, among patients who had the test, the likelihood of receiving the more favorable prescription increased almost six times. In fact, none of the skin-tested patients proved to have a penicillin allergy, and they also had more than double the chance of being discharged with a penicillin or cephalosporin prescription.

During the treatment guideline/decision support period, the likelihood that patients would receive a more favorable antibiotic prescription almost doubled over the standard of care period. Among the providers caring for the 199 medical patients during this period, 112 completed the decision support protocol and there were almost 300 unique webpage views of the guideline, which was accessible both at all hospital desktop computers and through mobile devices connecting to the secure hospital intranet. No adverse reactions occurred during either the standard-of-care or skin-test periods, and only one patient had a mild reaction—an itchy skin rash—to an amoxicillin dose after a negative penicillin skin test during the treatment guideline/decision support period.

Blumenthal notes that the guideline/decision support tool was not integrated into the electronic health record during the study period and that, as the tool becomes more available, it may have an even greater effect on antibiotic prescriptions. The tool has now been adopted at MGH, BWH, Newton-Wellesley Hospital, Brigham and Women's Faulkner Hospital and North Shore Medical Center—all members of Partners HealthCare System. Such a tool also could be useful for hospitals with limited ability to adopt a skin testing protocol or lack of access to staff allergy specialists.

"We found that addressing penicillin allergy by either method could lead to an overall improvement in antibiotic choice for these patients," Blumenthal says. "We don't want to discourage any method of evaluation because even thinking about whether a patient's penicillin allergy is true could lead a provider to make a different management decision. Even here at MGH, we estimated that skin testing all patients with recorded penicillin allergy would be impractical without a significant staff increase or technological guidance."

Wickner adds, "In our Partners system alone, we have more than 200,000 patients who carry this listed diagnosis in the electronic medical record. It is exciting to have safe and effective systems in place to improve the care of these patients when they are hospitalized."

Explore further: Many doctors still don't know facts about penicillin allergy

More information: Kimberly G. Blumenthal et al, Tackling Inpatient Penicillin Allergies: Tools for Antimicrobial Stewardship, Journal of Allergy and Clinical Immunology (2017). DOI: 10.1016/j.jaci.2017.02.005

Related Stories

Many doctors still don't know facts about penicillin allergy

November 11, 2016
If you think you're allergic to penicillin, but have never been tested, ask for a referral to an allergist to confirm the allergy. Many physicians whose patients have "penicillin allergy" in their charts don't know that frequently, ...

You might be allergic to penicillin—then again, you might not

November 7, 2014
Many people have been told, incorrectly, that they're allergic to penicillin, but have not had allergy testing. These people are often given alternative antibiotics prior to surgery to ward off infection. But when antibiotic ...

Consider penicillin, even if you have had a prior reaction

November 5, 2015
Most people who think they're allergic to penicillin have been told so by a doctor after they've had a reaction to the drug. And the majority, even though they've never been allergy tested, never take penicillin again.

Many patients mistakenly believe they are allergic to penicillin

May 5, 2016
It's time for your primary care check-up, and the doctor asks you to list any known drug allergies. "Penicillin," you say immediately, although you can't remember actually taking the drug or having a reaction to it—it was ...

Which comes first: Self-reported penicillin allergy or chronic hives?

February 3, 2016
People who have self-reported penicillin allergy may have a three times greater chance of suffering from chronic hives. And people who have chronic hives tend to self-report penicillin allergy at a three times greater rate ...

Penicillin skin testing can ID tolerance to beta-lactam agents

June 19, 2013
(HealthDay)—Penicillin skin testing (PST) can be used to identify whether patients will tolerate β-lactam, with a negative predictive value of 100 percent, according to a study published in the June issue of the Journal ...

Recommended for you

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Immune health maintained by meticulously ordered DNA

October 15, 2018
Walter and Eliza Hall Institute researchers have revealed how immune health is maintained by the exquisite organisation skills of a protein called Pax5.

New immunotherapy targeting blood-clotting protein

October 15, 2018
Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier—which keeps large molecules in the blood from entering the brain—becomes abnormally permeable, ...

Enzyme that triggers autoimmune responses from T-cells in patients with MS found

October 11, 2018
A team of researchers from Switzerland, the U.S. and Spain has isolated an enzyme that triggers an autoimmune response from T-cells in patients with MS. In their paper published in the journal Science Translational Medicine, ...

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.